View in EDS HTML Full Text PDF Full Text

Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): a phase 2 clinical trial.

Saved in:
Bibliographic Details
Title: Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): a phase 2 clinical trial.
Authors: Wei ZG; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China.; Sichuan Provincial Key Laboratory of Nuclear Physics and Medical Research, Sichuan University, Chengdu, People's Republic of China., Chen HJ; Department of Pathology, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Wang DJ; Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Jiang Z; Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Pei YY; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Li LY; Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Wang F; Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Jin J; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Liu ZR; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Chen F; Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, People's Republic of China. hxchenfei@163.com.; Head and Neck Surgical Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China. hxchenfei@163.com., Liu J; Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, People's Republic of China. junliu@wchscu.edu.cn.; Head and Neck Surgical Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China. junliu@wchscu.edu.cn., Peng XC; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China. pxx2014@163.com.; Sichuan Provincial Key Laboratory of Nuclear Physics and Medical Research, Sichuan University, Chengdu, People's Republic of China. pxx2014@163.com.
Source: Nature communications [Nat Commun] 2025 Oct 07; Vol. 16 (1), pp. 8918. Date of Electronic Publication: 2025 Oct 07.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41057358
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): a phase 2 clinical trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Wei+ZG%22">Wei ZG</searchLink>; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China.; Sichuan Provincial Key Laboratory of Nuclear Physics and Medical Research, Sichuan University, Chengdu, People's Republic of China.<br /><searchLink fieldCode="AU" term="%22Chen+HJ%22">Chen HJ</searchLink>; Department of Pathology, West China Hospital, Sichuan University, Chengdu, People's Republic of China.<br /><searchLink fieldCode="AU" term="%22Wang+DJ%22">Wang DJ</searchLink>; Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, People's Republic of China.<br /><searchLink fieldCode="AU" term="%22Jiang+Z%22">Jiang Z</searchLink>; Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, People's Republic of China.<br /><searchLink fieldCode="AU" term="%22Pei+YY%22">Pei YY</searchLink>; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China.<br /><searchLink fieldCode="AU" term="%22Li+LY%22">Li LY</searchLink>; Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, People's Republic of China.<br /><searchLink fieldCode="AU" term="%22Wang+F%22">Wang F</searchLink>; Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, People's Republic of China.<br /><searchLink fieldCode="AU" term="%22Jin+J%22">Jin J</searchLink>; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China.<br /><searchLink fieldCode="AU" term="%22Liu+ZR%22">Liu ZR</searchLink>; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China.<br /><searchLink fieldCode="AU" term="%22Chen+F%22">Chen F</searchLink>; Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, People's Republic of China. hxchenfei@163.com.; Head and Neck Surgical Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China. hxchenfei@163.com.<br /><searchLink fieldCode="AU" term="%22Liu+J%22">Liu J</searchLink>; Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, People's Republic of China. junliu@wchscu.edu.cn.; Head and Neck Surgical Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China. junliu@wchscu.edu.cn.<br /><searchLink fieldCode="AU" term="%22Peng+XC%22">Peng XC</searchLink>; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China. pxx2014@163.com.; Sichuan Provincial Key Laboratory of Nuclear Physics and Medical Research, Sichuan University, Chengdu, People's Republic of China. pxx2014@163.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101528555%22">Nature communications</searchLink> [Nat Commun] 2025 Oct 07; Vol. 16 (1), pp. 8918. <i>Date of Electronic Publication: </i>2025 Oct 07.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101528555 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-1723 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220411723%22">20411723 </searchLink><i>NLM ISO Abbreviation: </i>Nat Commun <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41057358
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41467-025-63978-y
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 8918
    Titles:
      – TitleFull: Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): a phase 2 clinical trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Wei ZG
      – PersonEntity:
          Name:
            NameFull: Chen HJ
      – PersonEntity:
          Name:
            NameFull: Wang DJ
      – PersonEntity:
          Name:
            NameFull: Jiang Z
      – PersonEntity:
          Name:
            NameFull: Pei YY
      – PersonEntity:
          Name:
            NameFull: Li LY
      – PersonEntity:
          Name:
            NameFull: Wang F
      – PersonEntity:
          Name:
            NameFull: Jin J
      – PersonEntity:
          Name:
            NameFull: Liu ZR
      – PersonEntity:
          Name:
            NameFull: Chen F
      – PersonEntity:
          Name:
            NameFull: Liu J
      – PersonEntity:
          Name:
            NameFull: Peng XC
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 07
              M: 10
              Text: 2025 Oct 07
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2041-1723
          Numbering:
            – Type: volume
              Value: 16
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Nature communications
              Type: main
ResultId 1